Anticancer combination therapy

A method of treating and/or preventing an oncological or hyperproliferative disease, said method comprising administering an SMAC mimetic in combination with a PD-1 antagonist to a patient in need thereof,

• wherein the SMAC mimetic is selected from any one of the following compounds 1 to 26;
• or a pharmaceutically acceptable salt thereof;
• and
• wherein the PD-1 antagonist is selected from the group consisting of pembrolizumab, nivolumab, pidilizumab, atezolizumab, avelumab, durvalumab, PDR-001, PD1-1, PD1-2, PD1-3, PD1-4 and PD1-5.